Float Short %

26.31

Margin Of Safety %

Put/Call OI Ratio

0.08

EPS Next Q Diff

-3.74

EPS Last/This Y

EPS This/Next Y

16.94

Price

4.07

Target Price

22.6

Analyst Recom

3.38

Performance Q

-38.74

Relative Volume

13.9

Beta

0.71

Ticker: BLUE

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-01-23	BLUE	7.9	0.08	0.01	84253
2025-01-24	BLUE	7.79	0.08	0.17	84236
2025-01-27	BLUE	7.58	0.08	3.86	84290
2025-01-28	BLUE	7.73	0.08	0.56	84233
2025-01-29	BLUE	7.51	0.08	8.83	84248
2025-01-30	BLUE	7.88	0.08	0.02	84570
2025-01-31	BLUE	7.75	0.08	0.44	84607
2025-02-03	BLUE	7.02	0.08	0.11	84616
2025-02-04	BLUE	6.95	0.08	0.03	84654
2025-02-05	BLUE	6.97	0.08	0.60	84786
2025-02-06	BLUE	6.65	0.08	0.03	84804
2025-02-07	BLUE	6.3	0.08	0.79	84903
2025-02-10	BLUE	6.24	0.08	0.15	85146
2025-02-11	BLUE	6.05	0.08	2.63	85146
2025-02-12	BLUE	6.4	0.08	0.09	85157
2025-02-13	BLUE	7.24	0.08	0.11	85170
2025-02-14	BLUE	7.28	0.08	0.33	85328
2025-02-18	BLUE	7.09	0.08	0.53	85341
2025-02-19	BLUE	7.24	0.08	0.41	85348
2025-02-20	BLUE	7.03	0.08	0.00	85439
2025-02-21	BLUE	4.1	0.08	2.77	85427
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-01-23	BLUE	7.87	63.1	-	-27.19
2025-01-24	BLUE	7.81	63.1	-	-27.19
2025-01-27	BLUE	7.57	63.1	-	-27.19
2025-01-28	BLUE	7.74	63.1	-	-27.19
2025-01-29	BLUE	7.53	63.1	-	-27.19
2025-01-30	BLUE	7.91	63.1	-	-27.19
2025-01-31	BLUE	7.74	63.1	-	-27.19
2025-02-03	BLUE	7.03	63.1	-	-27.19
2025-02-04	BLUE	6.93	63.1	-	-27.19
2025-02-05	BLUE	6.91	63.1	-	-27.19
2025-02-06	BLUE	6.69	63.1	-	-27.19
2025-02-07	BLUE	6.27	63.1	-	-27.19
2025-02-10	BLUE	6.29	63.1	-	-27.19
2025-02-11	BLUE	6.07	63.1	-	-27.19
2025-02-12	BLUE	6.40	63.1	-	-27.19
2025-02-13	BLUE	7.24	63.1	-	-27.19
2025-02-14	BLUE	7.27	63.1	-	-27.19
2025-02-18	BLUE	7.11	63.1	-	-27.19
2025-02-19	BLUE	7.25	63.1	-	-27.19
2025-02-20	BLUE	7.03	63.1	-	-27.19
2025-02-21	BLUE	4.07	63.1	-	-27.19
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-01-23	BLUE	-31.72	-29.15	25.04
2025-01-24	BLUE	-31.72	-29.15	25.04
2025-01-27	BLUE	-31.72	-21.42	25.04
2025-01-28	BLUE	-31.72	-21.42	25.07
2025-01-29	BLUE	-31.72	-21.42	25.07
2025-01-30	BLUE	-31.72	-21.42	25.07
2025-01-31	BLUE	-31.72	-21.42	25.07
2025-02-03	BLUE	-31.72	-15.66	25.07
2025-02-04	BLUE	-31.72	-15.66	25.07
2025-02-05	BLUE	-31.72	-15.66	25.07
2025-02-06	BLUE	-31.99	-15.66	25.07
2025-02-07	BLUE	-31.99	-15.66	25.07
2025-02-10	BLUE	-31.99	-10.83	25.07
2025-02-11	BLUE	-27.53	-10.83	25.12
2025-02-12	BLUE	-27.53	-10.83	26.28
2025-02-13	BLUE	-27.53	-10.83	26.28
2025-02-14	BLUE	-26.99	-10.83	26.31
2025-02-18	BLUE	-26.99	-21.17	26.31
2025-02-19	BLUE	-26.81	-21.17	26.31
2025-02-20	BLUE	-26.81	-21.17	26.31
2025-02-21	BLUE	-26.81	-21.17	26.31
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.31

Avg. EPS Est. Current Quarter

-5.75

Avg. EPS Est. Next Quarter

-4.04

Insider Transactions

-26.81

Institutional Transactions

-21.17

Beta

0.71

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.6

Max Drawdown 5-Year %

-99.4

Target Price

22.6

P/E

Forward P/E

PEG

P/S

0.75

P/B

P/Free Cash Flow

EPS

-35.97

Average EPS Est. Cur. Y

-27.19

EPS Next Y. (Est.)

-10.25

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-551.26

Relative Volume

13.9

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

0.9

EPS 1 30Days Diff

-0.19

EBIT Estimation

bluebird bio, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 282

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

stock quote shares BLUE – bluebird bio, Inc. Stock Price stock today

news today BLUE – bluebird bio, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch BLUE – bluebird bio, Inc. yahoo finance google finance

stock history BLUE – bluebird bio, Inc. invest stock market

stock prices BLUE premarket after hours

ticker BLUE fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: BLUE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y